DICE Therapeutics
Lisa Watson has a diverse work experience spanning various industries. Lisa started their career in 1997 as an Events coordinator at IMG and later worked at Mycroft Corp as a Production Manager. Lisa then transitioned to the role of Ballet Master at San Juan School of Dance before becoming a Procurement Manager at Sony. In 2002, they began working as a Ballet Teacher at the Academy of American Ballet while also serving as a Procurement Manager at Sony. In 2005, Lisa joined Clarke Consulting as an Accountant and worked there until 2008 when they joined Achaogen as a Senior Accountant. In 2012, they started their own Independent Finance Consulting business as an Independent Consultant. In 2013, Lisa joined DICE Therapeutics as a Controller and progressed to the role of Associate Director, Business Operations/Financial Planning & Analysis. Currently, Lisa holds the position of Director, Business Operations and Financial Planning and Analysis at DICE Therapeutics.
Lisa Watson earned their Bachelor of Science (BS) degree in International Business/Trade/Commerce from San Francisco State University, attending from 1994 to 1997. Lisa then pursued their Master of Business Administration (MBA) degree in Finance at Notre Dame de Namur University, studying from 2012 to 2014. Additionally, Lisa attended Castilleja, although the specific years and degree information for this educational institution are not provided.
DICE Therapeutics
At DICE Therapeutics, we design and develop innovative therapies in immunology for patients with debilitating disease. Seeking to create a future where convenient oral medicines with biologic-like efficacy are available to patients with serious medical conditions, we are developing oral alternatives to medicines currently limited to injectable forms. We believe that such pills will be widely appreciated by patients and doctors alike, as they provide a lower bar to entry than biologics, and as oral medicines can easily be co-formulated with other efficacious drugs. The combination of our core technology with additional, unique biophysical insights has enabled DICE to target protein-protein interactions with small molecules. In doing so, DICE has cracked open a previously intractable set of clinically validated therapeutic targets, including Interleukin-17 (IL-17). Our lead program – an orally bioavailable IL-17 antagonist for the treatment of psoriasis – is currently progressing through IND-enabling studies. In parallel, we continue to advance both partnered and internal pipeline drug discovery programs, providing a robust pre-clinical pipeline.